CN Patent

CN119789859A — 非酒精性脂肪肝病的治疗

Assigned to Arrowhead Pharmaceuticals Inc · Expires 2025-04-08 · 1y expired

What this patent protects

描述了经由降低需要治疗的人类受试者中HSD17B13的表达来治疗非酒精性脂肪肝病的方法。

USPTO Abstract

描述了经由降低需要治疗的人类受试者中HSD17B13的表达来治疗非酒精性脂肪肝病的方法。

Drugs covered by this patent

plozasiran-sodium (PLOZASIRAN SODIUM)

Patent Metadata

Patent number: CN119789859A
Jurisdiction: CN
Classification: —
Expires: 2025-04-08
Drug substance claim: No
Drug product claim: No
Assignee: Arrowhead Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.